Volume 11, Number 6—June 2005
Extended-spectrum β-Lactamase-producing Flora in Healthy Persons
To the Editor: Extended-spectrum β-lactamase (ESBL)–producing gram-negative bacilli are endemic in hospitals. In intensive care units, 2% prevalence of ESBL-producing organisms has been reported (1). Exceedingly high rates of ESBL-producing bacteria in Indian hospitals prompted us to look at the fecal carriage of ESBL in the community (2).
One hundred healthy executives received a comprehensive health check at our tertiary care center in central Mumbai from August to September 2004. The predominant isolates from stool samples obtained for routine examination were cultured, and initial screening for ESBL production was conducted by using the disk diffusion method according to NCCLS guidelines (3). For these isolates, the ESBL phenotypic confirmation was performed with ceftazidime-clavulanate for an increase in zone diameter by 5 mm (disk potentiation). In addition, the ATB BLSE strip (bioMérieux, Lyon, France) was used to confirm the presence of inhibitor (sulbactam)-susceptible enzymes and to differentiate the strains from those that were either inhibitor resistant or harboring other β-lactamases, such as those of AmpC derivation. The ATB BLSE strip consists of a varying concentration of ceftazidime, 0.5–32 mg/L, and aztreonam, 0.5–8 mg/L, with varying combinations of these agents with a β-lactamase inhibitor, i.e., + sulbactam, 0.06–1 mg/L. Cefotetan (4 and 32 mg/L) and imipenem (4 and 8 mg/L) were also included in the strip. The test was considered positive when a variation of ≥4 dilutions was observed between the antimicrobial agent tested alone and the agent combined with the inhibitor. Eleven of the 100 samples screened were positive for ESBL-producing Escherichia coli and Klebsiella pneumoniae. Seven of the 11 were confirmed by using the ATB BLSE strip. The MIC of ceftazidime and aztreonam in all 7 isolates was 8 μg/mL. We might be underreporting ESBL producers in these cases by not including the cefotaxime-clavulanate combination in addition to the ceftazidime-clavulanate concentration. The percentage resistance to ciprofloxacin was 45%. All isolates were susceptible to amikacin and the carbapenems. None of the executives gave a history of hospitalization in the last year or history of antimicrobial drug consumption in the last 6 months.
This trend in patients with no apparent risk factors for ESBL carriage calls for urgent attention. Unknown environmental factors are likely playing a key role in maintaining this selective pressure. Larger studies are required to substantiate these findings.
- Harris AD, Nemoy L, Johnson J, Carnahan M, Smith DJ, Standiford H, Co-carriage rates of vancomycin resistant Enterococcus and extended spectrum β-lactamases–producing bacteria among a cohort of intensive care unit patients—implications for an active surveillance program. Infect Control Hosp Epidemiol. 2004;25:105–8.
- Mathai D, Rhomberg PR, Biendenbach DJ, Jones RN; India Antimicrobial Resistance Study Group. Evaluation of the in vitro activity of six broad spectrum β–lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis. 2002;44:367–77.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th Informational Supplement; M100-S12 Wayne (PA): The Committee; 2002. p. 46.
Suggested citation for this article: Rodrigues C, Shukla U, Jog S, Mehta A. Extended-spectrum β-lactamase-producing flora in healthy persons [letter]. Emerg Infect Dis [serial on the Internet]. 2005 Jun [date cited]. http://dx.doi.org/10.3201/eid1106.041111
Please use the form below to submit correspondence to the authors or contact them at the following address:
Camilla Rodrigues, Consultant Microbiologist, P.D. Hinduja National Hospital and Medicine Research Centre, Mumbai, India 400016; fax: 91-22-2444-2318
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: April 24, 2012
- Page last updated: April 24, 2012
- Page last reviewed: April 24, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)